Newsletter | February 9, 2026

02.09.26 -- Why The EU Biotech Act Matters To The U.S.: A Clinical Perspective

PATIENT RECRUITMENT

Confronting "Time Toxicity" In Global Oncology And Rare Disease Trials For Operational Excellence And Patient Retention

Time is the only truly finite resource in a clinical trial. Consultant Leila Cupersmith discusses how sponsors can better design trials with a lower time burden to boost enrollment, retention, and overall operational excellence.

How Rescue Studies Utilize Direct-To-Patient Strategies

If your clinical trial struggles to overcome enrollment bottlenecks, a tech-enabled rescue strategy could be the solution.

The Problem-Solving, Patient Advocate Team That Every Trial Needs

Patient Kindness is a supplemental layer of premium support that offers a more seamless clinical trial experience for patients and caregivers with more complex or nuanced needs.

CLINICAL SITES

Why The EU Biotech Act Matters To The U.S.: A Clinical Perspective

The EU Biotech Act has across-the-pond implications, especially for U.S.-based biotech sponsors developing advanced therapy medicinal products (ATMPs, also called cell and gene therapies), oncology therapies, or other high-complexity modalities. Consultant Jessica Cordes explains.

The Case For Parallel Processing In Clinical Trial Start-Up

Stop letting outdated processes stall your innovation and learn how parallel processing transforms study start-up from a series of hurdles into a synchronized sprint.

Study Analysis – Site Payment Automation

By removing administrative bottlenecks, see how automation improves cash flow for sites, reduces operational burden for sponsors, and supports smoother, more predictable trial execution.

Optimizing Site Activation To Accelerate Clinical Trials

Clinical trial site activation delays are a major bottleneck in drug development, hampering trial timelines and funding flows. To reverse this trend, site-focused solutions are being prioritized.

It's Time To Move Into One Home for Sites

Explore a vendor- and sponsor-neutral platform that streamlines trial management by consolidating systems and tasks.

PATIENT CENTRICITY

Working (Well) With Patient Advocates: The Sponsor POV

Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

Why Flexible Payment Options Matter For Clinical Trial Participants

In clinical trials, offering a variety of payment options is critical for participant retention and overall study success. How can you make the payment process simple and flexible?

CHOOSE YOUR OWN ADVENTURE

You're receiving the Monday edition of the Clinical Leader newsletter, focusing on Clinical SitesPatient Centricity, and Patient Recruitment. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: